Ben Scruggs, PhD


Ben supports the firm’s new portfolio company diligence, existing portfolio strategy, and overall operations. Prior to joining Hatteras in 2016, Ben completed a postdoctoral fellowship in the Epigenetics and Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences. He has performed research in the fields of genomics, metabolism, RNA biology, and transcription regulation. His research has been published in peer-reviewed journals including Molecular Cell and Cell Metabolism, among others. 

Ben received his B.E. in biomedical engineering from Vanderbilt University and a Ph.D. in molecular cell biology from Washington University in St. Louis.


Ben is a director on the boards of IMMvention Therapeutix and Veralox Therapeutics. He also serves as a board observer at Altis Biosystems, Myeloid Therapeutics, Qpex Biopharma, and Trefoil Therapeutics. He was formerly a board observer at Dropworks (acquired in 2021) and Graybug Vision (Nasdaq: GRAY). He serves on NHLBI’s national network of mentors and the North Carolina Microbiome Consortium Steering Committee. He has served on various committees and panels for the National Cancer Institute, the Council for Entrepreneurial Development, and Southeast Life Sciences.